Kestra (KMTS) Q3 2026 earnings review
Revenue Surges 63% and Margins Expand, but Profitability Remains Distant
Kestra is executing a textbook 'land and expand' strategy in the wearable defibrillator market, delivering 63% revenue growth and expanding gross margins to 52.6%. The ASSURE system is rapidly taking share from incumbents, evidenced by a 58% jump in prescriptions. However, the cost of this growth is steep: adjusted operating expenses surged 46%, widening the EBITDA loss. Management raised FY26 guidance to $93M, but the recent equity raise underscores that Kestra is still a cash-burning growth machine far from self-sustainability.
🐂 Bull Case
Revenue beat expectations with 63% YoY growth to $24.6M, marking continuous sequential acceleration. The product is clearly resonating in the market, as evidenced by a 58% jump in prescriptions.
Gross margin expanded over 900 bps YoY to 52.6%, validating the unit economics of the rental model as the company successfully shifts its payer mix to in-network.
🐻 Bear Case
Despite higher gross profits, Adjusted EBITDA loss widened to $21.2M as adjusted operating expenses surged 46% to fund the sales force expansion. Operating leverage remains completely elusive.
To support its cash-burning operations, Kestra raised equity via a December offering, bringing the weighted-average share count from 19.9M a year ago to 55.8M, highlighting the dilutive nature of their growth phase.
⚖️ Verdict: ⚪
Neutral. Kestra is executing incredibly well on its top-line and gross margin metrics, proving product-market fit. However, the rapidly expanding operating losses and reliance on dilutive equity raises mean the stock is a pure growth play with significant execution risk on the long path to profitability.
Key Themes
Operating Leverage is Still Missing
Management is loud about their 63% revenue surge and gross margin expansion to 52.6%. However, looking below the gross profit line reveals a contradicting story. Despite generating $6.4M in incremental gross profit YoY, the Adjusted EBITDA loss actually widened from $16.3M to $21.2M. The company spent $11.3M in new adjusted operating expenses just to capture that gross profit. The cash burn machine is running hot, and operating leverage remains completely absent in this phase of the commercial rollout.
In-Network Payer Mix Unlocking Unit Economics
Gross margin expanded over 900 bps YoY to 52.6%. This is a structural improvement driven by a higher mix of in-network patients and better revenue cycle management. This proves the inherent leverage in Kestra's rental business model: as they bring the 'long tail' of payers under contract, revenue per fit expands without a corresponding increase in COGS.
Sales Force Expansion Driving Prescription Volumes
Prescriptions for the ASSURE system grew 58% YoY to 5,462. This acceleration is directly tied to the aggressive expansion of the sales organization from ~70 reps at the IPO to over 100, targeting high-volume WCD geographies. Management's strategic deployment of clinical specialist roles is successfully freeing up territory reps to open new accounts.
ACE PAS Clinical Data Catalyzing Adoption
The primary results from the FDA post-approval study (ACE PAS)—the largest prospective WCD study with over 21,000 patients—are serving as a powerful commercial driver. Kestra is leveraging data showing superior wear time (23.1 hours) and a 7.5% annualized SCA incidence to alter physician prescribing behavior, neutralizing competitor pushback and expanding the WCD market.
Biobeat Technologies Collaboration
Management announced a new strategic collaboration with Biobeat Technologies. Biobeat specializes in wearable, cuffless cardiovascular monitoring. Integrating advanced vital sign monitoring into the ASSURE platform represents a significant product innovation, capitalizing on Kestra's industry-leading patient compliance rate to build a more comprehensive digital healthcare ecosystem.
Execution Risk in Sales Force Ramp
Kestra plans to effectively double its IPO-level sales force count within months. While this aggressive hiring drives top-line growth, it introduces severe execution risk related to training, territory management, and maintaining target productivity levels for new reps, especially as they move beyond low-hanging, high-volume regions.
Uncertain Guideline Update Timeline
While the ACE PAS data is compelling, the path to a formal update of the 2017 clinical guidelines remains ad hoc with no firm timeline. Management admits their growth model doesn't rely on a guideline change, but the absence of this structural catalyst means market expansion will require costly, localized rep-by-rep education efforts to maintain momentum.
Other KPIs
Accelerating losses. The adjusted EBITDA loss widened by 30% from $(16.3) million a year ago and $(19.7) million in the prior quarter. Despite strong gross profit growth, the massive increase in SG&A to support the commercial buildout is completely offsetting top-line leverage.
Stable. Up from $237.6 million at the end of FY25. This balance was heavily boosted by a December 2025 public offering that yielded substantial net proceeds. The fortified balance sheet provides a multi-year runway to fund the operating cash burn (which was $63.0 million for the first nine months of FY26), significantly reducing near-term dilution risk.
Guidance
Accelerating. Management raised the full-year target from $91 million. The new guidance implies 55% YoY growth over FY25. With $66.5M generated YTD, this implies Q4 revenue of ~$26.5M, representing a 54% YoY increase and healthy sequential growth from Q3's $24.6M.
Key Questions
OpEx Run-Rate Expectations
Given the $11.3M YoY increase in adjusted operating expenses this quarter, what is the expected quarterly OpEx run-rate needed to support the $93M revenue guidance and continued commercial rollout into FY27?
Biobeat Monetization Strategy
How will the Biobeat Technologies collaboration be monetized? Is this an add-on subscription service, or a feature designed solely to drive higher base adoption of the ASSURE system?
Path to EBITDA Leverage
The adjusted EBITDA loss widened again this quarter. What specific productivity metrics or revenue thresholds must your new sales cohorts hit before we see absolute EBITDA loss dollars begin to decline?